Related Experiment Videos
The evolution of lung cancer screening
Neal W Wilkinson1, Gregory M Loewen, Donald L Klippenstein
1Division of Thoracic Surgical Oncology, State University of New York and Roswell Park Cancer Institute, Buffalo, New York 14263-0001, USA.
Journal of Surgical Oncology
|February 6, 2004
Summary
Lung cancer screening has evolved significantly. Modern methods like the Early Lung Cancer Action Project (ELCAP) can detect early-stage lung cancers, with future potential in molecular markers.
Area of Science:
- Pulmonology
- Oncology
- Medical Diagnostics
Background:
- Past lung cancer screening trials in the 1970s using chest X-ray (CXR) and sputum cytology did not show mortality reduction.
- The Early Lung Cancer Action Project (ELCAP) demonstrated the efficacy of modern screening in detecting Stage I lung cancers.
Purpose of the Study:
- To review the historical context and advancements in lung cancer screening.
- To highlight the potential of emerging molecular markers for future lung cancer detection.
Main Methods:
- Review of historical lung cancer screening trials.
- Analysis of findings from the Early Lung Cancer Action Project (ELCAP).
- Discussion of current understanding of pre-cancerous bronchial epithelial changes, including histologic and genetic alterations.
Main Results:
- Early lung cancer screening trials in the 1970s failed to demonstrate mortality benefits.
- The ELCAP demonstrated successful detection of Stage I lung cancers using modern screening techniques.
- Research is increasingly understanding the histologic and genetic changes in bronchial epithelium preceding cancer development.
Conclusions:
- Modern lung cancer screening methods, exemplified by ELCAP, show promise in early detection.
- Emerging molecular markers in sputum and serum represent a promising avenue for future lung cancer screening strategies.
- Continued research into pre-cancerous changes and molecular markers is crucial for improving lung cancer outcomes.